Focused On-demand Library for C-type lectin domain family 2 member A

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q6UVW9

UPID:

CLC2A_HUMAN

Alternative names:

Keratinocyte-associated C-type lectin; Proliferation-induced lymphocyte-associated receptor

Alternative UPACC:

Q6UVW9; A5Y4G5; A9QKS2; A9QKS3

Background:

C-type lectin domain family 2 member A, also known as Keratinocyte-associated C-type lectin and Proliferation-induced lymphocyte-associated receptor, plays a crucial role in immune response modulation. It enhances T-cell expansion and survival by upregulating anti-apoptotic proteins and may influence T-cell homing to lymph nodes. Additionally, it promotes natural killer cell mediated cytotoxicity towards keratinocytes through KLRF2 interaction.

Therapeutic significance:

Understanding the role of C-type lectin domain family 2 member A could open doors to potential therapeutic strategies, particularly in enhancing immune responses and developing targeted treatments for immune-related conditions.